NEKTAR THERAPEUTICS
Canonical company identity and public leadership record.
- Source reported. 8 claims from 3 sources.
- Not claimed by the company.
- Eval: not assessed.
- Chair
- Not published
- Board
- 1 directorAlpha calculation. Published seats
- Independence
- 0 of 1Alpha calculation
- Evidence
- 3 sources8 published claims
- Open conflicts
- 0None open
Leadership
3 claims| Person | Role | Since | Status | Evidence |
|---|---|---|---|---|
| Howard W. Robin | Director, President and Chief Executive Officer | Current | Source reportedE3 | |
| Jonathan Zalevsky, Ph.D. | Senior Vice President and Chief Research and Development Officer | Current | Source reportedE4 | |
| Sandra Gardiner | Interim Chief Financial Officer | Current | Source reportedE5 |
Board
1 claim| Director | Status | Since | Committees | Evidence |
|---|---|---|---|---|
| Howard W. Robin | Not independent | None published | Source reportedE2 |
Financial context
1 claim| Fact | Stated value | Evidence |
|---|---|---|
| Security listing | NKTR (NASDAQ) | Source reportedE1 |
Other published claims
3 claims| Fact | Stated value | Evidence |
|---|---|---|
| Legal name | NEKTAR THERAPEUTICS | Source reportedE1 |
| Entity status | Public listing published | Source reportedE1 |
| Published fact | US | Source reportedE1 |
Evidence
5 evidence records| Ref | Source | Authority | Source date | Retrieved | Rights | Cited by |
|---|---|---|---|---|---|---|
| E1 | Alpha canonical company public projectionCanonical identity | Open web | Not recorded | Rights not recorded, link only | 4 claims | |
| E2 | NEKTAR THERAPEUTICS DEF 14A 2026-04-24SEC proxy | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim | ||
| E3 | NKTR 10-K executive officersSEC filing | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim | ||
| E4 | NKTR 10-K executive officersSEC filing | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim | ||
| E5 | NKTR 10-K executive officersSEC filing | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim |
No evidence record is pinned or signed yet.
Not yet in this record
These parts of a company record have no published claims yet. That is a coverage state, not a finding about the company. 1 further claim is under review.
- Committees
- Control and voting
- Governance
- Risk
- AI oversight
- Legal
- Compensation
Index memberships
No current membership is published in Alpha's tracked index universe.
This is not evidence that the company is absent from every market index.
As of 22 Nov 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Coverage states the record reports (13)
- Corporate structure
- Not reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- Committees
- Not reviewed. Committee mandates show where oversight is delegated.
- Ownership
- Not reviewed. Ownership and voting power determine who can influence the board.
- Financials
- Not reviewed. Governance-relevant financial context frames capital and audit decisions.
- Compensation
- Not reviewed. Pay design shows how incentives are governed.
- Governance
- Not reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governance
- Not reviewed. Meeting and vote records show shareholder dissent and support.
- Audit
- Not reviewed. Auditor, controls and restatements show assurance over reporting.
- Legal
- Not reviewed. Material legal and regulatory matters show enforcement exposure.
- Risk
- Not reviewed. Risk ownership links the board, committees, executives and controls.
- Cyber
- Not reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governance
- Not reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets external
- Not reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
Limits of this record (5)
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.
History
Version public-1Published .
- CEO role recorded. Howard W. Robin executive of NEKTAR THERAPEUTICS, effective 13 Mar 2026.Effective . Recorded .
- Executive appointed. Jonathan Zalevsky, Ph.D. executive of NEKTAR THERAPEUTICS, effective 13 Mar 2026.Effective . Recorded .
- CFO role recorded. Sandra Gardiner executive of NEKTAR THERAPEUTICS, effective 13 Mar 2026.Effective . Recorded .
- Director appointed. Howard W. Robin seat on NEKTAR THERAPEUTICS, effective 2007.Effective . Recorded .
About this record
- Alpha ID
- alpha:company:2798b261-6f57-4da0-9929-59629c27007e
- Version
- public-1:ro-d751713988987e9331980363e24189ce
- Identity
- Not claimed
- Evidence
- Source reported
- Evaluation
- Not assessed
- Monitoring
- Not monitored yet
- Authority
- Not published
- Freshness
- Current
- Integrity
- Not signed yet
- Basis
- Published company record built from public sources
- Never published
- Private company data: deployments, authority grants, TrustChecks, receipts, telemetry
The company can claim this record and correct or dispute any claim. Corrections are versioned and the original stays in history. A company's own statements are shown as its own and never replace the cited evidence.

